Earlier this week ATAI Life Sciences AG has successfully secured $43 million in Series B funding which valued the company at $240 million. This round makes ATAI the most valuable company in the space of psychedelic medicine.
The raised capital will be used to further finance ATAI’s platform technology, develop the existing drug pipeline, and acquire additional compounds. ATAI is currently funding clinical trials for psilocybin, which were initiated with the FDA approval of “Breakthrough Therapy” for Compass Pathways, where ATAI is the largest investor.
The financing round was led by Subversive Capital and included other renowned VC and PE firms in the health tech space. QC·VENTURES has also participated in the round following its Series A investment in October last year.
The news first appeared on CNBC (see article).
About ATAI Life Sciences
ATAI is an internationally active biotech company investing in and acquiring therapeutics focusing on longevity and mental wellbeing. The company’s vision is to cure mental health disorders, enabling people to live healthier and happier lives.